A new gene therapy company based in the Netherlands has raised €31 million in seed financing to advance a preclinical portfolio of potential treatments for muscular and neurodegenerative disorders. VectorY Therapeutics BV was launched in October 2020 to develop vectorised antibodies using an adeno-associated virus vector platform and antibody-based targeted degradation technologies.
